Literature DB >> 25296733

Clinical utility of certain biomarkers as predictors of breast cancer with or without metastasis among Egyptian females.

Samia A Ahmed1, Manal A Hamed, Omar S Omar.   

Abstract

The objective of this study is to explore and correlate the value of certain biomarkers in breast cancer (BC) females with and without metastasis after undergoing the surgical treatment protocol in the National Cancer Institute in Egypt. Thirty females (33-69 years), diagnosed as early breast cancer patients with or without metastasis, and 20 healthy individuals were selected for this study. The biomarkers under investigation were vascular endothelial growth factor (VEGF), C-reactive protein (CRP), interleukin-6 (IL-6), and interleukin-8 (IL-8). The correlation between these markers and the tumor grade was also evaluated. The results revealed a significant increase (p < 0.0001) in VEGF, CRP, IL-6, and IL-8 in breast cancer patients with or without metastasis as compared to the healthy group. Surgical treatment of metastatic BC females showed a significant reduction of those parameters by variable degrees, whereas BC females without metastasis recorded the most inhibition levels. Also, there was positive correlation (p < 0.0001) between those biomarkers and the tumor grades. We also noticed an association between VEGF and IL-8 as well as CRP and IL-6. In conclusion, the selected biomarkers may be beneficial for the prognosis of breast cancer and seem to be a diagnostic tool to differentiate between BC with or without metastasis. The descried surgical treatment protocol succeeded to attenuate the elevated biomarker levels and improve patient survival which deserves more extensive studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25296733     DOI: 10.1007/s13277-014-2689-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  The importance of platelet counts and their contents in cancer.

Authors:  Henk M W Verheul; Herbert M Pinedo
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 3.  Biomarkers in cancer staging, prognosis and treatment selection.

Authors:  Joseph A Ludwig; John N Weinstein
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

4.  Inhibition of estrogen-dependent breast cell responses with phenylacetate.

Authors:  S Sawatsri; D Samid; S Malkapuram; N Sidell
Journal:  Int J Cancer       Date:  2001-09-01       Impact factor: 7.396

Review 5.  Cytokines in tumour growth, migration and metastasis.

Authors:  R P Negus; F R Balkwill
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

6.  N-acetylglucosaminidase, myeloperoxidase and vascular endothelial growth factor serum levels in breast cancer patients.

Authors:  Bertha Andrade Coelho; Andrezza Vilaça Belo; Sílvia Passos Andrade; Washington Cançado Amorim; Gilberto Uemura; Agnaldo Lopes da Silva Filho
Journal:  Biomed Pharmacother       Date:  2013-11-08       Impact factor: 6.529

7.  Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis.

Authors:  Patrizia Pasanisi; Elisabetta Venturelli; Daniele Morelli; Luigi Fontana; Giorgio Secreto; Franco Berrino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07       Impact factor: 4.254

8.  Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer.

Authors:  A M Al Murri; J M S Bartlett; P A Canney; J C Doughty; C Wilson; D C McMillan
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

Review 9.  A systematic review of the association between circulating concentrations of C reactive protein and cancer.

Authors:  Katriina Heikkilä; Shah Ebrahim; Debbie A Lawlor
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

10.  Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients.

Authors:  Verena Engelstaedter; Sabine Heublein; Anamur Lan Schumacher; Miriam Lenhard; Helen Engelstaedter; Ulrich Andergassen; Margit Guenthner-Biller; Christina Kuhn; Brigitte Rack; Markus Kupka; Doris Mayr; Udo Jeschke
Journal:  BMC Cancer       Date:  2012-12-15       Impact factor: 4.430

View more
  2 in total

1.  Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Authors:  Kala Visvanathan; MaryJo S Fackler; Zhe Zhang; Zoila A Lopez-Bujanda; Stacie C Jeter; Lori J Sokoll; Elizabeth Garrett-Mayer; Leslie M Cope; Christopher B Umbricht; David M Euhus; Andres Forero; Anna M Storniolo; Rita Nanda; Nancy U Lin; Lisa A Carey; James N Ingle; Saraswati Sukumar; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

2.  Community-based participatory research to improve life quality and clinical outcomes of patients with breast cancer (DianaWeb in Umbria pilot study).

Authors:  Milena Villarini; Chiara Lanari; Daniele Nucci; Vincenza Gianfredi; Tiziana Marzulli; Franco Berrino; Alessandra Borgo; Eleonora Bruno; Giuliana Gargano; Massimo Moretti; Anna Villarini
Journal:  BMJ Open       Date:  2016-06-01       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.